Creo Medical Group's EBIT per Share for the
six
months ended in Dec. 2025 was $-0.11.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.06.
During the past 3 years, the average EBIT per Share Growth Rate was 33.90% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 22.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Creo Medical Group's EBIT per Share or its related term are showing as below:
CMEOF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -83.9 Med: -5 Max: 33.9
Current: 33.9
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Creo Medical Group was 33.90% per year. The lowest was -83.90% per year. And the median was -5.00% per year.
CMEOF's 3-Year EBIT Growth Rate is ranked better than 80.75% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs CMEOF: 33.90
Creo Medical Group (OTCPK:CMEOF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Creo Medical Group EBIT per Share Related Terms
Creo Medical Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for Creo Medical Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creo Medical Group (CMEOF) has a EBIT per Share of $-0.06 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Creo Medical Group and its competitors. According to the industry distribution chart, Creo Medical Group ranks #133 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 19.2%.
Is Creo Medical Group's EBIT per Share too high?
Creo Medical Group's current EBIT per Share is $-0.06. Based on the distribution chart, Creo Medical Group ranks #133 out of 691 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Creo Medical Group has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Creo Medical Group's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Creo Medical Group ranks #133 out of 691 companies for EBIT per Share. This places Creo Medical Group in the top 19% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Creo Medical Group and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creo Medical Group's current EBIT per Share is $-0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creo Medical Group stock overvalued right now?
Creo Medical Group (CMEOF) has a current EBIT per Share of $-0.06. The stock's GF Value™ is $0.25, compared to a current price of $0.20 — trading 20% below its estimated fair value. The current EBIT per Share is $-0.06. Creo Medical Group's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Creo Medical Group (CMEOF), the current EBIT per Share is $-0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creo Medical Group (CMEOF) Overvalued in 2026?
Based on GuruFocus' analysis, Creo Medical Group stock appears to be undervalued.
The current stock price of $0.20 is trading 20% below its estimated GF Value™ of $0.25.
Key valuation signals for CMEOF:
EBIT per Share: $-0.06
GF Value™: $0.25 vs. price of $0.20 (20% below fair value)
No single metric tells the full story. See the CMEOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
52GF Score
Get the complete analysis for CMEOF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CMEOF has been successfully added to your 
